Vanguard Capital Management
KTTA icon

Vanguard Capital Management’s Pasithea Therapeutics KTTA Stock Holding History

Vanguard Capital Management’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65K Buy
126,279
+72,464
+135% +$49.9K ﹤0.01% 3916
2026
Q1 		$39.9K Buy
+53,815
New +$45K ﹤0.01% 3940

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Vanguard Capital Management's KTTA Position: Q2 2026 in Review

Vanguard Capital Management increased its Pasithea Therapeutics (KTTA) stake by 135% in Q2 2026, buying an estimated $49.9K and bringing the position to 126,279 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #3916.

Vanguard Capital Management first reported a position in KTTA in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Vanguard Capital Management held 126,279 shares of Pasithea Therapeutics worth $65K as of Q2 2026.
  • Vanguard Capital Management bought 72,464 Pasithea Therapeutics shares in Q2 2026, an estimated $49.9K.
  • Pasithea Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3916 holding.
  • Vanguard Capital Management first reported a position in Pasithea Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.